Home > Boards > US Listed > Biotechs > Eloxx Pharmaceuticals Inc. (ELOX)

The applications of Senesco's SNS10T in cancer are

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals GlobeNewswire Inc. - 10/27/2020 7:30:10 AM
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire Inc. - 10/22/2020 8:57:31 AM
Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020 GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant GlobeNewswire Inc. - 9/14/2020 10:06:20 AM
Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Confer... GlobeNewswire Inc. - 8/26/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2020 7:55:55 AM
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 P... GlobeNewswire Inc. - 8/12/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:16:56 AM
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:51:30 AM
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis GlobeNewswire Inc. - 8/4/2020 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:05 PM
Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020 GlobeNewswire Inc. - 7/28/2020 12:33:50 PM
Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 GlobeNewswire Inc. - 7/21/2020 2:17:29 PM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics GlobeNewswire Inc. - 7/15/2020 1:08:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2020 4:47:30 PM
Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily ... GlobeNewswire Inc. - 6/17/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 3:04:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:12:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:25 PM
investora2z   Wednesday, 11/20/13 11:48:06 AM
Re: None
Post # of 773 
The applications of Senesco's SNS10T in cancer are discussed much more than its applications in the field of agriculture. Due to the possible benefits like increasing crop yield, the agricultural applications also hold tremendous potential. The company already has licensing arrangements with other companies, and there is small inflow related to this. As mentioned in the recently filed 10Q for the period ending Sep 30, the company received a revenue of $100,000 which pertains to a milestone payment in connection with an agricultural license agreement. The agricultural applications have the potential to generate regular inflow for the company sooner compared to the cancer therapy applications. The encouraging results in pre-clinical and the clinical trials for cancer treatment have taken away the focus from the agricultural applications. Further, the recent news about the company is also mainly related to the upcoming results of the trials on multiple myeloma. The potential of agricultural applications is underrated. This is especially true if one considers the numerous partnerships which the company has, and the patents it owns. Senesco has agreements with companies like Bayer Crop Science and Monsanto. In November 2006, it had entered into a collaboration with Bayer Crop Science to use the technology on Brassica oilseeds to improve the yield of canola. Its agreement with Monsanto in 2007 enabled the use of Senesco's yield and stress technology on corn and soybeans. Other companies with which it has agreements include Cal/West Seeds, ArborGen and Rahan Meristem. The original discovery of eIF5A was actually in plants, and the human applications were tried because the genetic sequence of eIF5A (Factor 5A) is similar to that of a plant. In any case, the immediate trigger will be the upcoming update in early December on the clinical trials related to multiple myeloma (cohort 3). Positive news will help in building momentum for the stock.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences